Medical Wellness Association Awards ‘Superfood' Status to Mega Sardines
Recognized by the Medical Wellness Association as the world's first seafood 'Superfood,' Mega Sardines sets a new standard in health and nutrition.
MANILA, PHILIPPINES, May 19, 2025 / EINPresswire.com / -- The story began with an article published by none other than the esteemed Harvard University in 2023, extolling the benefits of 'eating down the seafood chain'—in other words, eating sardines. What was their basis? To start, the health benefits are tremendous. In a world facing increasing metabolic health concerns, the blend of protein and Omega-3 fats, with virtually no carbohydrates, makes sardines a perfect fit for metabolic health.
Additionally, sardines are among the most nutrient-dense foods on the planet, containing abundant levels of vitamin B12, vitamin D, calcium, selenium, phosphorus, iron, iodine, and CoQ10.
Finally, because they are small fish low on the food chain, sardines have a significantly lower risk of containing mercury, unlike larger fish species.
It's no wonder Harvard Health dedicated a report to sardines and other small marine foods as part of its mission to educate the public. The full report can be read here.
The United States-based Medical Wellness Association—the world's leading organization of health, wellness, and medical professionals with over 6,000 members—then took a closer look. Are certain sardine brands better than others? Are all processing methods the same? They focused specifically on what happens to sardines after they are wild-caught at sea.
One brand stood out: Mega Sardines, from the Philippines.
What gives Mega Sardines the edge is their vertical integration and innovative approach. Unlike companies that lease fishing fleets (often resulting in poor control over quality and freshness), Mega owns its entire fleet and enforces strict protocols to ensure maximum freshness and hygiene. This allows them to achieve an industry-leading 'catch to can in under 12 hours'—an unprecedented processing speed that delivers the freshest wild-caught sardines to consumers. Compared to the industry norm of several days, this 12-hour process ensures superior nutrient preservation and freshness.
Based on the nutritional profile of sardines, combined with Mega's unique processing method, the Medical Wellness Association has done something unprecedented in its 30+ year history: it has granted Mega Sardines the classification of 'Superfood'—the first seafood product in the world to receive this designation.
Dr. Christopher Breuleux, President and Founder of the Medical Wellness Association, remarked:
'Mega Sardines can play a vital role in helping consumers around the world combat metabolic and cardiovascular disease. It is truly a gift from nature for human health, and the processing is done with exceptional care to preserve freshness all the way to the dinner table. It is, indeed, a 'Superfood' everyone should increase their intake of.'
The innovative Mega approach traces back to the company's founder, William Tiu Lim. From the very beginning—five decades ago—Tiu Lim's mission was clear and noble: to provide cost-effective, nutritious meals for low-income households in his native Philippines. The pride on his face is evident as he holds the Medical Wellness Association's certificate—validation of a vision realized over the past 50 years.
'Today, Mega Sardines is no longer just a fishing company, but a global wellness company. We aim to help improve the health and wellness of consumers around the world. This is a legacy and a mission worth fighting for,' said Tiu Lim.
So next time you're planning a healthy meal, you just might find yourself saying,
'Honey, please pass the sardines.'
KD
KATAPULT DIGITAL CORP.
email us here
Visit us on social media:
LinkedIn
Instagram
Facebook
TikTok
Legal Disclaimer:
EIN Presswire provides this news content 'as is' without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
42 minutes ago
- Yahoo
From September, Singapore mandates measles shots for helpers in homes with unvaccinated kids
SINGAPORE, June 11 — From September 1, all domestic helpers in Singapore working in homes with children under the age of seven who are not fully vaccinated against measles must themselves be immunised, the country's Ministry of Manpower (MOM) announced yesterday. The move is aimed at safeguarding 'unvaccinated young children who are at higher risk of serious health complications from measles infections', said MOM, as reported by Channel News Asia (CNA). Singapore has already recorded 10 measles infections in 2025 as of the week ending May 10, just one shy of the total 11 cases reported in all of 2024, according to the Ministry of Health. Employers applying for or renewing work permits for migrant domestic workers (MDWs) must now declare: Whether the domestic helper is already vaccinated or immune to measles Whether all children under seven in the household are fully vaccinated If unvaccinated, whether a vaccination appointment has been booked Domestic helpers may be exempted if they are already immune — either through previous infection or past vaccination — or if all children under seven in the home have been fully immunised. Proof of immunity, such as vaccination records or serology test results, may be required. Employers are advised to check their domestic helper's immunity status well before permit renewal. Households with immunocompromised members are also strongly encouraged to verify their helper's measles immunity or arrange for vaccination. To meet the requirement, domestic helpers must receive two doses of the MMR (measles, mumps, and rubella) vaccine, spaced at least 28 days apart. The vaccine is available at private GP clinics, with the cost to be paid by employers. MOM also warned against false declarations. 'If employers with children below seven years old are found with MDWs who are not immune against measles, their work pass privileges may be suspended until vaccination proof is submitted,' the ministry said. Random checks and documentary audits will be conducted to ensure compliance. While Singapore maintains high overall vaccination rates — over 95 per cent for the first MMR dose and 90 per cent for the second among resident two-year-olds — sporadic cases are expected, MOM said, citing the 'highly transmissible nature of the disease'. The Communicable Diseases Agency (CDA) stressed that despite strong local immunity, 'the surge in measles cases globally and regionally continues to pose public health risks, particularly for those without measles immunity'. Measles, which spreads through airborne droplets, has been part of Singapore's compulsory childhood immunisation schedule since 1985.
Yahoo
an hour ago
- Yahoo
Kelun-Biotech Announces Breakthrough Therapy Designation Granted for Sacituzumab Tirumotecan (Sac-TMT) in Combination With Tagitanlimab in China for Certain Types of Non-Small Cell Lung Cancer
CHENGDU, China, June 10, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") today announced that its TROP2-directed antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT) (佳泰莱®) in combination with the PD-L1 monoclonal antibody tagitanlimab (科泰莱®) was granted Breakthrough Therapy Designation by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) of China for the first-line treatment of locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) without actionable genomic alterations. Breakthrough Therapy Designation is granted for treatment options that demonstrate significant clinical advantages over currently available treatments and is aimed at expediting the research, development and marketing of innovative treatment options that address clinically urgent medical needs. This designation is based on the efficacy and safety data from the non-squamous cohort of the Phase II OptiTROP-Lung01 study. This marks the fifth Breakthrough Therapy Designation granted to sac-TMT by the NMPA. Sac-TMT has previously received this designation for: Locally advanced or metastatic triple-negative breast cancer (TNBC) in July 2022; EGFR-mutant, locally advanced or metastatic NSCLC after progression on EGFR-TKI therapy in January 2023; Locally advanced or metastatic hormone-receptor positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-) breast cancer (BC) in patients who have previously received at least two lines of systemic chemotherapy in June 2023； First-line treatment of unresectable locally advanced, recurrent or metastatic PD-L1 negative TNBC in March 2024. Results from a Phase 2 OptiTROP-Lung01 study of sac-TMT in combination with tagitanlimab in first-line advanced or metastatic non-squamous NSCLC patients were presented in a poster session at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting[1]. Dr. Michael Ge, CEO of Kelun-Biotech said, "This designation by the NMPA highlights the importance of developing novel therapeutic options for diverse NSCLC subtypes. Sac-TMT in combination with tagitanlimab demonstrated clinically meaningful outcomes in key endpoints for patients with non-squamous NSCLC without actionable genomic alterations as a first-line treatment. We are excited about the therapeutic potential of TROP2 ADC- immunotherapy combinations, and we look forward to working with regulatory authorities in China to bring this combination therapy to patients in need as soon as possible." [1] Abstract #8529: Lung Cancer – Non-Small Cell Metastatic, ASCO Annual Meeting, 2025 About sac-TMT (佳泰莱®)Sac-TMT, a core product of the Company, is a novel human TROP2 ADC in which the Company has proprietary intellectual property rights, targeting advanced solid tumors such as NSCLC, BC, gastric cancer (GC), gynecological tumors, among others. Sac-TMT is developed with a novel linker to conjugate the payload, a belotecan-derivative topoisomerase I inhibitor with a drug-to-antibody-ratio (DAR) of 7.4. Sac-TMT specifically recognizes TROP2 on the surface of tumor cells by recombinant anti-TROP2 humanized monoclonal antibodies, which is then endocytosed by tumor cells and releases KL610023 intracellularly. KL610023, as a topoisomerase I inhibitor, induces DNA damage to tumor cells, which in turn leads to cell-cycle arrest and apoptosis. In addition, it also releases KL610023 in the tumor microenvironment. Given that KL610023 is membrane permeable, it can enable a bystander effect, or in other words kill adjacent tumor cells. In May 2022, the Company licensed the exclusive rights to MSD (the tradename of Merck & Co., Inc., Rahway, NJ, USA) to develop, use, manufacture and commercialize sac-TMT in all territories outside of Greater China (includes Mainland China, Hong Kong, Macao, and Taiwan). To date, two indications for sac-TMT have been approved and marketed in China for the treatment of adult patients with unresectable locally advanced or metastatic TNBC who have received at least two prior systemic therapies (at least one of them for advanced or metastatic setting) and EGFR mutation-positive locally advanced or metastatic non-squamous NSCLC following progression on EGFR-TKI therapy and platinum-based chemotherapy. Sac-TMT became the first domestic ADC with global intellectual property rights to be fully approved for marketing. It is also the world's first TROP2 ADC to be approved for marketing in a lung cancer indication. In addition, two new indication applications for sac-TMT for the treatment of adult patients with EGFR-mutant locally advanced or metastatic NSCLC who progressed after treatment with EGFR-TKI therapy and with unresectable locally advanced, metastatic HR+/HER2- BC who have received prior endocrine therapy and other systemic treatments in the advanced or metastatic setting were accepted by the CDE, and were included in the priority review and approval process. As of today, the Company has initiated 8 registrational clinical studies in China. MSD has initiated 14 ongoing Phase 3 global clinical studies of sac-TMT as a monotherapy or with pembrolizumab2 or other agents for several types of cancer. These studies are sponsored and led by MSD. About Tagitanlimab (科泰莱®)Tagitanlimab is the first PD-L1 mAb globally to receive authorization for the first-line treatment of NPC. Previously, the NMPA has approved the marketing in China of tagitanlimab used in combination with cisplatin and gemcitabine for the first-line treatment of patients with R/M NPC and monotherapy for the treatment of patients with recurrent or metastatic NPC who have failed after prior 2L+ chemotherapy, respectively. About Kelun-BiotechKelun-Biotech ( is a holding subsidiary of Kelun Pharmaceutical ( which focuses on the R&D, manufacturing, commercialization and global collaboration of innovative biological drugs and small molecule drugs. The company focuses on major disease areas such as solid tumors, autoimmune, inflammatory, and metabolic diseases, and in establishing a globalized drug development and industrialization platform to address the unmet medical needs in China and the rest of world. The Company is committed to becoming a leading global enterprise in the field of innovative drugs. At present, the Company has more than 30 ongoing key innovative drug projects, of which 3 projects have been approved for marketing, 1 project is in the NDA stage, and more than 10 projects are in the clinical stage. The company has established one of the world's leading proprietary ADC platforms, OptiDC™, and has 1 ADC project approved for marketing, 1 ADC project in NDA stage, and multiple ADC and novel DC assets in clinical or preclinical research stage. For more information, please visit Media: klbio_pr@ View original content to download multimedia: SOURCE Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Yahoo
an hour ago
- Yahoo
Blue Planet Prize 2025: Announcement of Prize Laureates
TOKYO, June 11, 2025--(BUSINESS WIRE)--This year marks the 34th awarding of the Blue Planet Prize, the international environmental award sponsored by the Asahi Glass Foundation, chaired by Takuya Shimamura. Every year, the Foundation selects two laureates, individuals, or organizations who have made significant contributions to the resolution of global environmental problems. The Board of Directors has selected the following 2025 Blue Planet Prize laureates. 1. Professor Robert B. Jackson (USA) Born on September 26, 1961Department of Earth System Science, Stanford University Professor Robert B. Jackson is an expert on the carbon cycle in terrestrial ecosystems, including forests, grasslands, and wetlands. He has conducted pioneering research on the relationship between soil, vegetation, and soil bacterial communities. In addition, he has quantified the balance of greenhouse gases, such as carbon dioxide, methane, and nitrous oxide, from natural ecosystems and from fossil fuel use. Since 2017, he has served as chair of the Global Carbon Project (GCP), leading efforts to monitor and reduce greenhouse gas emissions. 2. Dr. Jeremy Leggett (UK) Born on March 16, 1954Founder and CEO of Highlands Rewilding chairman of the Carbon Tracker Initiative Dr. Jeremy Leggett, as the inaugural chairman of the Carbon Tracker Initiative (CTI), introduced the concept of the "carbon bubble," highlighting the economic risks associated with fossil fuel assets. Through CTI's activities, he influenced investors and policymakers, advancing the divestment movement. In addition, as a practical effort to balance economic activity with environmental conservation, he founded one of the UK's leading solar energy companies. More recently, he has been spearheading initiatives in Scotland to connect ecological restoration with community prosperity. Each laureate is presented with a certificate of merit, a commemorative trophy, and 500,000 US dollars in prize money. The Award Ceremony is scheduled on Wednesday, October 29, 2025, at Tokyo Kaikan. Commemorative lectures will be given on October 30th and November 1st, 2025, at the University of Tokyo and at the Kyoto International Community House (kokoka), respectively. View source version on Contacts Toshihiro Tanuma, PhDTHE ASAHI GLASS FOUNDATION2nd Floor, Science Plaza, 5-3 Yonbancho Chiyoda-ku, Tokyo 102-0081 JapanPhone +81-3-5275-0620e-mail: post@ URL: Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
